Key points from article :
Korify Capital is putting together a $100 million venture fund targeting biotech space.
Plans to invest in 15 to 20 companies across Europe, the U.S. and Israel.
Research is about to get translated into human applications in the coming years.
Great progress on the animal front and can actually do quite a lot. They're already prolonging lifespan.
COVID-19 accelerated the interest of generalist investors in longevity and it could spur innovation in mental health sector.
Korify sees room for smaller biotechs to build on academic progress, creating investment opportunities for the new VC fund.
Cambrian Biopharma is the first investment, which disclosed $160 million to advance 14 drug candidates designed to target aging.
